Cerebrospinal Fluid Biochemical Studies in Patients with Parkinson's Disease: Toward a Potential Search for Biomarkers for This Disease

Overview

Journal Front Cell Neurosci

Specialty Cell Biology

Date 2014 Nov 27

PMID 25426023

Citations 40

Authors

Felix J Jimenez-Jimenez

Hortensia Alonso-Navarro

Elena Garcia-Martin

Jose A G Agundez

Affiliations

Soon will be listed here.

Abstract

The blood-brain barrier supplies brain tissues with nutrients and filters certain compounds from the brain back to the bloodstream. In several neurodegenerative diseases, including Parkinson's disease (PD), there are disruptions of the blood-brain barrier. Cerebrospinal fluid (CSF) has been widely investigated in PD and in other parkinsonian syndromes with the aim of establishing useful biomarkers for an accurate differential diagnosis among these syndromes. This review article summarizes the studies reported on CSF levels of many potential biomarkers of PD. The most consistent findings are: (a) the possible role of CSF urate on the progression of the disease; (b) the possible relations of CSF total tau and phosphotau protein with the progression of PD and with the preservation of cognitive function in PD patients; (c) the possible value of CSF beta-amyloid 1-42 as a useful marker of further cognitive decline in PD patients, and (d) the potential usefulness of CSF neurofilament (NFL) protein levels in the differential diagnosis between PD and other parkinsonian syndromes. Future multicentric, longitudinal, prospective studies with long-term follow-up and neuropathological confirmation would be useful in establishing appropriate biomarkers for PD.

Citing Articles

Evaluation of the Landscape of Pharmacodynamic Biomarkers in GM1 and GM2 Gangliosidosis.

Stern S, Crisamore K, Li R, Pacanowski M, Schuck R Clin Transl Sci. 2025; 18(3):e70176.

PMID: 40016926 PMC: 11868035. DOI: 10.1111/cts.70176.

Biological Function Analysis of MicroRNAs and Proteins in the Cerebrospinal Fluid of Patients with Parkinson's Disease.

Hwang J, Kim S, George N, Kwon M, Jang Y, Lee S Int J Mol Sci. 2025; 25(24.

PMID: 39769025 PMC: 11678473. DOI: 10.3390/ijms252413260.

Omega-3 Attenuates Disrupted Neurotransmission and Partially Protects Metabolic Dysfunction Caused by Obesity in Wistar Rats.

de Farias Fraga G, da Silva Rodrigues F, Jantsch J, Silva Dias V, Milczarski V, Wickert F Neurochem Res. 2024; 49(10):2763-2773.

PMID: 38960951 DOI: 10.1007/s11064-024-04201-0.

Clinical biomarkers for Lewy body diseases.

Abdelmoaty M, Lu E, Kadry R, Foster E, Bhattarai S, Mosley R Cell Biosci. 2023; 13(1):209.

PMID: 37964309 PMC: 10644566. DOI: 10.1186/s13578-023-01152-x.

Biomarkers of Parkinson's Disease: From Basic Research to Clinical Practice.

Ma Z, Wang Z, Zhang F, Liu H, Mao L, Yuan L Aging Dis. 2023; 15(4):1813-1830.

PMID: 37815899 PMC: 11272192. DOI: 10.14336/AD.2023.1005.

References

Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, DAmore C . Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry. 2008; 64(10):850-5. DOI: 10.1016/j.biopsych.2008.02.016. View

Bjorkhem I, Lovgren-Sandblom A, Leoni V, Meaney S, Brodin L, Salveson L . Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci Lett. 2013; 555:102-5. DOI: 10.1016/j.neulet.2013.09.003. View

Teychenne P, Ziegler M, Lake C, Enna S . Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon. Ann Neurol. 1982; 11(1):76-9. DOI: 10.1002/ana.410110113. View

Carvey P, McRae A, Lint T, Ptak L, Lo E, Goetz C . The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology. 1991; 41(5 Suppl 2):53-8; discussion 59-60. DOI: 10.1212/wnl.41.5_suppl_2.53. View

Ishibashi K, Kanemaru K, Saito Y, Murayama S, Oda K, Ishiwata K . Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease. Acta Neurol Scand. 2009; 122(1):46-51. DOI: 10.1111/j.1600-0404.2009.01255.x. View

Mally J, Szalai G, Stone T . Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. J Neurol Sci. 1997; 151(2):159-62. DOI: 10.1016/s0022-510x(97)00119-6. View

Tohgi H, Abe T, Takahashi S, Takahashi J, Hamato H . Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neurosci Lett. 1993; 159(1-2):135-8. DOI: 10.1016/0304-3940(93)90817-5. View

Zubenko G, Marquis J, Volicer L, Direnfeld L, Langlais P, Nixon R . Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. Biol Psychiatry. 1986; 21(14):1365-81. DOI: 10.1016/0006-3223(86)90328-8. View

Nishi K, Kondo T, Narabayashi H, Takubo H, Muramoto S, Araki H . Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid. J Neurol Sci. 1989; 92(1):65-70. DOI: 10.1016/0022-510x(89)90175-5. View

10.

Pankonin M, Sohi J, Kamholz J, Loeb J . Differential distribution of neuregulin in human brain and spinal fluid. Brain Res. 2009; 1258:1-11. DOI: 10.1016/j.brainres.2008.12.047. View

11.

Tohgi H, Abe T, Hashiguchi K, Takahashi S, Nozaki Y, Kikuchi T . A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degeneration. Neurosci Lett. 1991; 126(2):155-8. DOI: 10.1016/0304-3940(91)90542-2. View

12.

Curzon G, Godwin-Austen R, Tomlinson E, Kantamaneni B . The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry. 1970; 33(1):1-6. PMC: 493400. DOI: 10.1136/jnnp.33.1.1. View

13.

Qureshi G, Qureshi A, Memon S, Parvez S . Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy. J Neural Transm Suppl. 2007; (71):229-36. DOI: 10.1007/978-3-211-33328-0_24. View

14.

Liu D . [The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment]. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1989; 22(2):95-8, 126-7. View

15.

Holmberg B, Rosengren L, Karlsson J, Johnels B . Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord. 1998; 13(1):70-7. DOI: 10.1002/mds.870130116. View

16.

Hagihara M, Mihara R, Togari A, Nagatsu T . Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: changes in patients with Parkinson's disease. Biochem Med Metab Biol. 1987; 37(3):360-5. DOI: 10.1016/0885-4505(87)90049-1. View

17.

McLellan D, Chalmers R, Johnson R . Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism. Acta Neurol Scand. 1975; 51(1):74-82. DOI: 10.1111/j.1600-0404.1975.tb01360.x. View

18.

Tohgi H, Abe T, Takahashi S, Kikuchi T . The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1993; 6(2):119-26. DOI: 10.1007/BF02261005. View

19.

Jesse S, Lehnert S, Jahn O, Parnetti L, Soininen H, Herukka S . Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia. PLoS One. 2012; 7(11):e48783. PMC: 3493604. DOI: 10.1371/journal.pone.0048783. View

20.

Konings C, Kuiper M, Teerlink T, Mulder C, Scheltens P, Wolters E . Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J Neurol Sci. 1999; 168(2):112-5. DOI: 10.1016/s0022-510x(99)00167-7. View